Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro.
about
Viperin (cig5), an IFN-inducible antiviral protein directly induced by human cytomegalovirusSynergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitroActive cytomegalovirus particles in the eyes of an AIDS patient being treated with 9-[2-hydroxy-1-(hydroxymethyl) ethoxymethyl] guanine (Ganciclovir)Treatment of cytomegalovirus retinitis with ganciclovir (9-[2-hydroxy-1-(hydroxymethyl) ethoxymethyl] guanine (BW B759U)Inhibition of varicella-zoster virus-induced DNA polymerase by a new guanosine analog, 9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine triphosphate(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replicationActivity of 9-(1,3-dihydroxy-2-propoxymethyl)guanine compared with that of acyclovir against human, monkey, and rodent cytomegalovirusesEffect of antiviral agents on replication of herpes simplex virus type 1 in brain culturesAcyclic guanosine analogs as inhibitors of human cytomegalovirusEffect of ganciclovir [9-(1,3-dihydroxy-2-propoxymethyl)guanine] on viral DNA and protein synthesis in cells infected with herpes simplex virusPyrrolo[2,3-d]pyrimidine nucleosides as inhibitors of human cytomegalovirusAntiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell cultureEffects of 9-(1,3-dihydroxy-2-propoxymethyl)guanine, a new antiherpesvirus compound, on synthesis of macromolecules in herpes simplex virus-infected cellsInhibition of human cytomegalovirus replication by 9-(1,3-dihydroxy-2-propoxymethyl)guanine alone and in combination with human interferonsEffects of the nucleoside analog 2'-nor-2'-deoxyguanosine on human cytomegalovirus replicationGanciclovir prophylaxis for cochlear pathophysiology during experimental guinea pig cytomegalovirus labyrinthitis.The role of ganciclovir for the management of cytomegalovirus retinitis in HIV patients: Pharmacological review and update on new developments.Activation of the mitogen-activated protein kinase p38 by human cytomegalovirus infection through two distinct pathways: a novel mechanism for activation of p38.Human cytomegalovirus up-regulates the phosphatidylinositol 3-kinase (PI3-K) pathway: inhibition of PI3-K activity inhibits viral replication and virus-induced signalingMetabolic activation of 9([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human lymphoblastoid cell lines infected with Epstein-Barr virusAcyclovir is phosphorylated by the human cytomegalovirus UL97 protein.Lobucavir is phosphorylated in human cytomegalovirus-infected and -uninfected cells and inhibits the viral DNA polymeraseToxicity trial of prophylactic 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine (ganciclovir) after marrow transplantation in dogsFoscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.9-(1-3-Dihydroxy-2-propoxymethyl)guanine prevents death but not immunity in murine cytomegalovirus-infected normal and immunosuppressed BALB/c mice.Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on the acute local phase of herpes simplex virus-induced skin infections in mice and the establishment of latency.Efficacy of 2'-nor-2'-deoxyguanosine treatment for orofacial herpes simplex virus type 1 skin infections in miceA point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives.Antiviral therapy: current concepts and practicesAcquisition of cytomegalovirus infection: an update.Human cytomegalovirus induces expression of cellular topoisomerase II.Two specific topoisomerase II inhibitors prevent replication of human cytomegalovirus DNA: an implied role in replication of the viral genome.Preparation and ocular pharmacokinetics of ganciclovir liposomes.Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements.Herpesvirus and enteric viral infections in bone marrow transplantation: clinical presentations, pathogenesis, and therapeutic strategies.Ganciclovir--a review of pharmacology, therapeutic efficacy and potential use for treatment of congenital cytomegalovirus infections.Biodegradable polymeric device for sustained intravitreal release of ganciclovir in rabbits.Kinome Profiling Identifies Druggable Targets for Novel Human Cytomegalovirus (HCMV) Antivirals.Population pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. NIAID Collaborative Antiviral Study Group.Selective inhibition of human cytomegalovirus replication by a novel nucleoside, oxetanocin G.
P2860
Q24292060-EC95CFF2-9E13-49EA-91AA-8AFA131D5045Q28330357-FD992EAB-FC01-46DF-B293-4883660304CEQ28359826-E8FA342D-1DF7-444C-ACC5-21237A8EFC41Q28359848-97ED782D-9AB1-4646-B7C3-39C2B53BCE20Q28359883-302B7B33-0CD2-4D6A-BE4E-0265858A38D2Q28359995-22D6DCE9-C87F-4A49-9477-E8B210158571Q28360393-CCD8E0BB-F809-4646-BDE5-6EF8EEC4155CQ28360513-A20EBDD9-45F2-4FBE-BFB0-EE8971F898B8Q28360560-A08E8B11-22D5-40D2-B058-2C814B501199Q28360564-625AE9F1-8C0D-4F0F-B746-0424A74881ECQ28360591-06202918-F65F-4FF6-A11F-75FC86F43B63Q28361902-2DCEF457-3A6C-4A36-8955-4B4D05F79DAAQ28365697-4EE6380C-0DD9-456C-B6C6-1296D993C91BQ28365700-A8B350DB-0539-446D-9FCC-30A5CA959425Q28366318-EF399E1F-851B-4CDE-8E32-501D98EA99B8Q30502919-0793B193-EB02-4D1C-A7D6-089110511D7CQ33400808-0D089C4B-50A4-4A02-BE37-085D6163CED0Q33793056-57302823-E58E-4D9A-B9C1-593FE9AA5BBCQ33842473-99EC3697-75E1-4E65-9482-509A4890918AQ33928152-92D30A17-BFD0-43F8-A834-19A7189810FDQ33977394-D2378A1A-0426-4B9F-A82A-2AA8D1259545Q35139402-00D154C2-743D-4839-B9F4-5B4448B5EA28Q35292930-D7DE14AB-D0A4-48B0-B8D0-E335159E1BCAQ35333512-780B8369-766E-4CFF-9133-37AF81336E28Q35540779-82EC50D6-CEE5-4ADB-97CD-12B4798F6395Q35644370-F7A3ACD8-B680-4024-8182-4A8176305144Q35756914-26B4B6FB-73A8-4687-8D10-8E0DD649CC44Q35807437-29143CF5-B189-484A-92FF-B28EB0D4C3AFQ36070394-6ECE05E0-3DA0-483A-AAEB-9518A2FE8487Q36635110-4B1E9809-7374-4FA9-BF5C-4FAD822CBD79Q36798224-2D844419-0E9E-47EE-A88A-AA611053DA56Q36874653-A384153B-F940-4589-9FCC-FB78636F90BBQ37361985-E270CFFA-6D97-497E-951B-A3BF5FB82C16Q37570464-D077A388-AB0D-40EC-B3B7-EE966435B133Q37901418-E345145B-1A85-4AF2-8939-C9A2C75E9354Q38305554-2E688620-2857-481B-AEB3-8E1CEC621F09Q38557085-ACDB61A0-4283-4664-A602-F77F5715DC22Q38941812-1FF1152C-B801-484A-AD87-EDC17B447C42Q39782822-80BFE8E4-58CE-4CEA-A64B-DE9DD1422C6DQ39818514-1C7D96F9-DB3A-4EC6-9BF6-F22545A86FAA
P2860
Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro.
description
1983 nî lūn-bûn
@nan
1983年の論文
@ja
1983年論文
@yue
1983年論文
@zh-hant
1983年論文
@zh-hk
1983年論文
@zh-mo
1983年論文
@zh-tw
1983年论文
@wuu
1983年论文
@zh
1983年论文
@zh-cn
name
Effect of 9-(1,3-dihydroxy-2-p ...... alovirus replication in vitro.
@ast
Effect of 9-(1,3-dihydroxy-2-p ...... alovirus replication in vitro.
@en
type
label
Effect of 9-(1,3-dihydroxy-2-p ...... alovirus replication in vitro.
@ast
Effect of 9-(1,3-dihydroxy-2-p ...... alovirus replication in vitro.
@en
prefLabel
Effect of 9-(1,3-dihydroxy-2-p ...... alovirus replication in vitro.
@ast
Effect of 9-(1,3-dihydroxy-2-p ...... alovirus replication in vitro.
@en
P2093
P2860
P356
P1476
Effect of 9-(1,3-dihydroxy-2-p ...... alovirus replication in vitro.
@en
P2093
P2860
P304
P356
10.1128/AAC.24.4.518
P407
P577
1983-10-01T00:00:00Z